Melatonin affects cell proliferation in a variety of tumor cell lines, both in physiological and pharmacological concentrations. This research group has demonstrated that a melatonin analogue, called agomelatine, inhibits the growth of cell lines of colon cancer in vitro and in vivo, suggesting the oncostatic / cytotoxic role of this compound.

Advantages

This pharmaceutical composition may be administered by any suitable method, such as intravenous infusion and oral, topical or parenteral routes. The combined use with other components is proposed, as well as the preparation of a food composition as a nutritional or dietary supplement.

Intellectual Property

This technology is protected by patent.

Aims

This research group is looking to establish a license agreement or agreement for public-private partnership for the development of technology.

Classification

Area: Therapy
Technology: Drug Delivery
Pathology: Oncology